The American Association of Clinical Endocrinology (AACE) has released its 2025 Consensus Statement and updated algorithm for the management of adults with dyslipidemia, offering concise visual guidance and tables to support clinical decision-making aimed at reducing atherosclerotic cardiovascular disease (ASCVD) and triglyceride-induced pancreatitis risk. Developed by an international multidisciplinary task force, the update builds upon the 2020 AACE algorithm and integrates current evidence and expert consensus. The 2025 algorithm outlines guiding principles for patient-centered management, comprehensive risk assessment, identification of genetic dyslipidemias, lifestyle interventions, LDL-cholesterol–lowering pharmacotherapy, approaches to statin-associated muscle symptoms, and management strategies for hypertriglyceridemia and special populations—including older adults, those receiving transgender care or HIV treatment, and pregnant or lactating individuals. Aligned with the 2025 AACE Clinical Practice Guideline for Pharmacologic Management of Dyslipidemia and consistent with other international guidance, this update emphasizes individualized therapy, ASCVD and pancreatitis risk assessment, and the integration of health equity, cost-effectiveness, and risk–benefit considerations into dyslipidemia management. Source: https://www.endocrinepractice.org/
A rigorous cohort study utilizing Taiwan’s National Health Insurance Database provides robust evidence that SGLT2…
A new study investigating the link between cerebral microbleeds (CMBs) and dementia has found that…
A comprehensive prospective study tracking over 159,000 adults for up to three decades has provided…
A comprehensive new Cochrane review of 22 studies involving nearly 2,000 participants over six months…
A large-scale study involving 103,649 UK Biobank participants has revealed that adhering to healthy dietary…
To address uncertainties in statin safety profiles, which are often based on observational data susceptible…
This website uses cookies.